Skip to main content
SpringerLink
Log in

ULFS 49 CL, a prototype of a novel pharmacological concept

  • Conference paper
Sinus node inhibitors

Abstract

In patients with stable angina pectoris, ischemic attacks during exercise or other stress are caused by an imbalance between myocardial oxygen demand and oxygen supply. Current anti-ischemic drug therapy is aimed to extend exercise tolerance by an improvement of the O2-demand/supply ratio. Antianginal drugs have been traditionally categorized as vasodilators mainly increasing O2-supply (e.g., calcium-channel blockers, nitrates) and heart-rate-reducing drugs (e.g., β-adrenoceptor blockers), or combinations thereof (e.g., verapamil or diltiazem-like calcium-channel blockers). The conventional view of the mechanism of action of β-adrenoceptor blockers is relief of ischemia by a decrease of myocardial O2-demand during exercise due to reductions of heart rate and contractility. However, the benefit of the negative inotropic effect of β-adrenoceptor blockers remains in dispute. The attenuation of exercise-induced tachycardia and the preservation of an adequate diastolic perfusion time was often suggested as the only therapeutic principle of β-adrenoceptor blockers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Brown HF (1982) Electrophysiology of the sinoatrial node. Physiol Rev 62: 505–530

    PubMed  CAS  Google Scholar 

  2. Dämmgen J, Kadatz R, Diederen W (1981) Cardiovascular actions of 5,6-dimethoxy-2-[3[[α-(3,4-dimethoxy)-phenylethyl]-methylamino]propyl]phtalimidine (AQ-A 39), a specific bradycardic agent. Arzneim Forsch 31: 666–670

    Google Scholar 

  3. Dämmgen JW, Lamping KA, Gross GJ (1985) Actions of two new bradycardic agents, AQ-AH 208 and ULFS 49 CL, on ischemic myocardial perfusion and function. J Cardiovasc Pharmacol 7: 71–79

    Article  PubMed  Google Scholar 

  4. Denyer JC, Brown HF (1990) Pacemaking in rabbit isolated sino-atrial node cells during Cs+ block of the hyperpolarization-activated current if. J Physiol (London) 429: 401–409

    CAS  Google Scholar 

  5. Di Francesco D, Ferroni A, Mazzanti M, Tromba C (1986) Properties of the hyperpolarizing- activated current (if) in cells isolated from the rabbit sino-atrial node. J Physiol (London) 377: 61–88

    Google Scholar 

  6. Doerr Th, Trautwein W (1990) On the mechanism of the “specific bradycardic action” of the verapamil derivative ULFS 49 CL. Naunyn Schmiedeberg’s Arch Pharmacol 341: 331–340

    Article  CAS  Google Scholar 

  7. Gruber R, Lumper G, Zilberszac A, Heistracher P (1983) Effects of 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methyhmino]propyl]-2H-3-benzazepin- 2-on hydrochloride (ULFS 49 CL) on the action potential of the guinea-pig heart. Naunyn Schmiedeberg’s Arch Pharmacol 324: R 32

    Google Scholar 

  8. Guth BD, Heusch G, Seitelberger R, Ross J Jr (1987) Elimination of exercise-induced myocardial dysfunction by a bradycardic agent in dogs with coronary artery stenosis. Circulation 75: 661–669

    Article  PubMed  CAS  Google Scholar 

  9. Hagiwara N, Irisaawa H, Kameyama M (1988) Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol (London) 395: 233–253

    CAS  Google Scholar 

  10. Harron DWG, Shanks RG (1985) Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidine. Eur Heart J 6: 722–729

    PubMed  CAS  Google Scholar 

  11. Indolfi C, Guth BD, Miura T, Miyazaki S, Schulz R, Ross J Jr (1989). Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on ULFS 49 CL in swine. Circulation 80: 983–993

    Article  PubMed  CAS  Google Scholar 

  12. Kobinger W (1989) Specific bradycardic agents. In: Vaughan Williams EM, Campbell TJ (eds) Handbook of experimental pharmacology, Vol. 89. Springer-Verlag, Berlin Heidelberg, pp 423–452

    Google Scholar 

  13. Kobinger W, Lillie C (1981) AQ-A 39 (5,6-dimethoxy-2[3[[α-(3,4-dimethoxy)phenyle- thyl]methylamino]propyl]phtalimidine), a specific bradycadic agent with direct action on the heart. Eur J Pharmacol 72: 153–164

    Article  PubMed  CAS  Google Scholar 

  14. Kobinger W, Lillie C (1984) Alinidine. In: Scriabine A (ed) New drugs annual: Cardiovascular drugs, vol 2. Raven Press, New York, pp 193–210

    Google Scholar 

  15. Kobinger W, Lillie C (1984) Cardiovascular characterization of ULFS 49 CL, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new “specific bradycardic agent”. Eur J Pharmacol 104: 9–18

    Article  PubMed  CAS  Google Scholar 

  16. Kobinger W, Lillie C (1987) Specific bradycardic agents—a novel pharmacological class? Eur Heart J 8 ( Suppl. L): 7–15

    Google Scholar 

  17. Kobinger W, Lillie C (1988) Falipamil (AQ-A 39) and ULFS 49 CL. Cardiovascular Drug Reviews 6: 35–53

    Article  Google Scholar 

  18. Kobinger W, Lillie C, Pichler L (1979) Cardiovascular actions of N-allyl-clonidine (ST 567), a substance with specific bradycardic action. Eur J Pharmacol 58: 141–150

    Article  PubMed  CAS  Google Scholar 

  19. Krumpl G, Schneider W, Raberger G (1986) Can exercise-induced regional contractile dysfunction be prevented by selective bradycardic agents? Naunyn Schmiedeberg’s Arch Pharmacol 334: 540–543

    Article  PubMed  CAS  Google Scholar 

  20. Krumpl G, Winkler M, Schneider W, Raberger G (1988) Comparison of the haemodynamic effects of the selective bradycardic agent ULFS 49 CL, with those of propranolol during treadmill exercise in dogs. Br J Pharmacol 94: 55–64

    PubMed  CAS  Google Scholar 

  21. Lillie C, Kobinger W (1983) Cardiovascular actions of ULFS 49 CL, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new “specific bradycardic agent”. Naunyn Schmiedeberg’s Arch Pharamcol 324: R 33

    Google Scholar 

  22. Lillie C, Kobinger W (1986) Investigations into the bradycardic effects of ULFS 49 CL (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyhenyl)ethyl]methylimino]propyl]- 2H-3-benzazepin-2-on hydrochloride) in isolated guinea pig atria. J Cardiovasc Pharmacol 8: 791–797

    PubMed  CAS  Google Scholar 

  23. Opt Hof T, Bouman LN (1988) personal communication. In: Kobinger W, Lillie C. Falipamil (AQ-A 39) and ULFS 49 CL. Cardiovascular Drug Reviews 6: 35–53

    Article  Google Scholar 

  24. Raberger G, Krumpl G, Schneider W (1987) Effects of the bradycardic agent ULFS 49 CL on exercise-induced regional contractile dysfunction in dogs. Int J Cardiol 14: 343–354

    Article  PubMed  CAS  Google Scholar 

  25. Reiffen M, Eberlein, W, Müller P, Psiorz M, Noll K, Heider J, Lillie C, Kobinger W, Luger P (1990) Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties. J Med Chem 33: 1496–1504

    Article  PubMed  CAS  Google Scholar 

  26. Riley DC, Gross GJ, Kampine KP, Warltier DC (1987) Specific bradycardic agents, a new therapeutic modality for anaesthesiology: hemodynamic effects of ULFS 49 CL and propranolol in conscious and isoflurane-anesthetized dogs. Anaesthesiology 67: 707–716

    Article  CAS  Google Scholar 

  27. Ross J Jr (1989) Mechanisms of regional ischemia and antianginal drug action during exercise. Prog Cardiov Dis 31: 455–466

    Article  Google Scholar 

  28. Tytgat J, Van Bogaert PP, Vereecke J, Carmeliet E (1990) Sensitivity of ventricular L-type Ca Channels to the bradycardic agents AQ-A 39, ULFS 49 CL and DK-AH 3. In: Vereeke J, Van Bogaert PP, Verdonck F (eds) Ionic currents and Ischemia. Leuven University Press, pp 276–278

    Google Scholar 

  29. Van Bogaert PP, Goethals M (1987) Pharmacological influence of specific bradycardic agents on the pacemaker current of sheep cardiac Purkinje fibres. A comparison between three different molecules. Eur Heart J 8 ( Suppl. L): 35–42

    Google Scholar 

  30. Van Bogaert PP, Goethals M, Simoens C (1990) Use- and frequency-dependent blockade by ULFS 49 CL of the if pacemaker current in sheep cardiac Purkinje fibres. Eur. J Pharmacol 187: 241–256

    Article  PubMed  Google Scholar 

  31. Van Ginneken ACG, Bouman LN, Jongsma HJ, Duivenvoorden JJ, Opt Hof T, Giles WR (1987) Alinidine as a model of the mode of action of specific bradycardic agents on SA node activity. Eur Heart J 8 ( Suppl. L): 25–33

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bender+Co Ges mbH, Research and Development, A-1121, Vienna, Austria

    Christian Lillie

Authors
  1. Christian Lillie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wallenberg Laboratory for Cardiovascular Research Sahlgren’s Hospital, Gothenburg University, S-41345, Gothenburg, Sweden

    Å. Hjalmarson (Professor of Cardiology) (Professor of Cardiology)

  2. Cardiovascular Research Foundation, STICARES, Valkeniersweg 79, NL-3075 AZ, Rotterdam, The Netherlands

    W. J. Remme

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Lillie, C. (1991). ULFS 49 CL, a prototype of a novel pharmacological concept. In: Hjalmarson, Å., Remme, W.J. (eds) Sinus node inhibitors. Steinkopff. https://doi.org/10.1007/978-3-642-72458-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72458-9_2

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-0861-3

  • Online ISBN: 978-3-642-72458-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation